Masimo Corporation (MASI)
NASDAQ: MASI · Real-Time Price · USD
146.41
-1.59 (-1.07%)
At close: Oct 28, 2025, 4:00 PM EDT
146.50
+0.09 (0.06%)
After-hours: Oct 28, 2025, 6:11 PM EDT
Masimo Revenue
Masimo had revenue of $370.90M in the quarter ending June 28, 2025, with 7.85% growth. This brings the company's revenue in the last twelve months to $2.15B, up 25.86% year-over-year. In the year 2024, Masimo had annual revenue of $2.09B with 2.26% growth.
Revenue (ttm)
$2.15B
Revenue Growth
+25.86%
P/S Ratio
3.66
Revenue / Employee
$598,278
Employees
3,600
Market Cap
7.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 28, 2024 | 2.09B | 46.30M | 2.26% |
| Dec 30, 2023 | 2.05B | 12.30M | 0.60% |
| Dec 31, 2022 | 2.04B | 796.60M | 64.28% |
| Jan 1, 2022 | 1.24B | 95.50M | 8.35% |
| Jan 2, 2021 | 1.14B | 205.86M | 21.95% |
| Dec 28, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 29, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 2, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
MASI News
- 5 days ago - Halper Sadeh LLC Encourages Masimo Corporation Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 7 days ago - Masimo to Report Third Quarter 2025 Financial Results after Market Close on Tuesday, November 4 - Business Wire
- 19 days ago - Masimo to Host Investor Day on December 3, 2025 - Business Wire
- 21 days ago - In Feasibility Study for Large, Prospective, Real-World Trial, Masimo SET® Performed Accurately on Critically Ill Adult ICU Patients of All Skin Tones - Business Wire
- 5 weeks ago - Masimo Completes Sale of Consumer Audio Business to HARMAN International - Business Wire
- 5 weeks ago - HARMAN Completes Sound United Acquisition to Expand Premium Audio Leadership - Business Wire
- 5 weeks ago - New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs - Business Wire
- 6 weeks ago - Masimo Announces Expansion of Strategic Partnership with Philips - Business Wire